• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: EDWARDS LIFESCIENCES CARPENTIER-EDWARDS PERIMOUNT THEON PERICARDIAL BIOPROSTHESIS; REPLACEMENT HEART-VALVE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

EDWARDS LIFESCIENCES CARPENTIER-EDWARDS PERIMOUNT THEON PERICARDIAL BIOPROSTHESIS; REPLACEMENT HEART-VALVE Back to Search Results
Model Number 6900PTFX29
Medical Device Problem Codes Fluid/Blood Leak (1250); Gradient Increase (1270)
Health Effect - Clinical Code Insufficient Information (4580)
Date of Event 01/03/2022
Type of Reportable Event Serious Injury
Event or Problem Description
It was reported that a patient with a 29mm 6900ptfx pericardial mitral valve was placed under consideration for a valve-in-valve procedure after an implant duration of six (6) years, five (5) months due to mitral stenosis and regurgitation.
 
Additional Manufacturer Narrative
The investigation is still in progress; therefore, a conclusion has yet to be established.A supplemental report will be submitted accordingly upon investigation completion.Edwards will continue to review and monitor all reported events.Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed.
 
Additional Manufacturer Narrative
The device history record (dhr) review was completed and this device passed all manufacturing and sterilization inspections prior to release for distribution.Stenosis, which develops progressively over time, can be due to a number of issues.Additionally, there can be a number of potential known and unknown patient-related contributing factors.Structural valve deterioration (svd) is the most common reason for bioprosthesis explant and encompasses multiple failure modes, including calcification, noncalcific degeneration, dehiscence, cusp thickening or fibrosis, or a combination of these.Such failure modes, occurring singularly or concomitantly, may contribute to stenosis and/or regurgitation.Alternatively, non-structural valve dysfunction (nsvd) may also play a role in the development of valvular stenosis.Stenosis is most commonly related to patient factors and is not usually an indication of a device malfunction.
 
Event or Problem Description
It was reported that a patient with a 29mm 6900ptfx pericardial mitral valve underwent a valve-in-valve procedure after an implant duration of six (6) years, six (6) months due to mitral stenosis and regurgitation.The tmvr procedure was performed with a 29mm 9600tfx transcatheter valve.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CARPENTIER-EDWARDS PERIMOUNT THEON PERICARDIAL BIOPROSTHESIS
Common Device Name
REPLACEMENT HEART-VALVE
Manufacturer (Section D)
EDWARDS LIFESCIENCES
1 edwards way
irvine CA 92614
Manufacturer (Section G)
EDWARDS LIFESCIENCES
1 edwards way
irvine CA 92614
Manufacturer Contact
reginald santos
1 edwards way
irvine, CA 92614
9492502731
MDR Report Key13385890
Report Number2015691-2022-03680
Device Sequence Number4678178
Product Code DYE
UDI-Device Identifier00690103163605
UDI-Public(01)00690103163605(17)190316
Combination Product (Y/N)N
Initial Reporter CountryUS
PMA/510(K) Number
P860057/S02
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2015
Serviced by Third Party (Y/N)Unknown
Reporter Type Manufacturer
Report Source Consumer,Health Professional,Company Representative
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 03/11/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Expiration Date03/16/2019
Device Model Number6900PTFX29
Device Catalogue Number6900PTFX29
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 01/03/2022
Supplement Date Received by Manufacturer02/28/2022
Initial Report FDA Received Date01/28/2022
Supplement Report FDA Received Date03/11/2022
Date Device Manufactured03/17/2015
Patient Sequence Number1
Outcome Attributed to Adverse Event Hospitalization; Life Threatening; Required Intervention;
Patient Age44 YR
Patient SexMale
-
-